TruScreen Group Limited announced that the private medical services provider, Dr. Sulaiman Al-Habib Medical Group (DSAMG), has recently completed the analysis of results from its cervical screening clinical evaluation of TruScreen Ultra and Liquid Based Cytology (LBC). A cohort of 507 women were examined with TruScreen and LBC across multiple medical centres of DSAMG. The preliminary results confirmed that TruScreen's sensitivity was 83.3% (LBC: 66%) and specificity was 95% (LBC 98%).
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.019 NZD | 0.00% | 0.00% | -17.39% |
05-30 | TruScreen Group Limited Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
05-30 | Truscreen's Fiscal Year 2024 Loss Widens | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-17.39% | 6.49M | |
+8.15% | 217B | |
+15.63% | 195B | |
+31.09% | 112B | |
+3.76% | 65.83B | |
+14.66% | 52.67B | |
+4.70% | 49.86B | |
-3.80% | 38.18B | |
-0.48% | 35.39B | |
+23.37% | 31.02B |
- Stock Market
- Equities
- TRU Stock
- News TruScreen Group Limited
- TruScreen Group Limited Announces Clinical Evaluation Results from Saudi Arabia